News & Events
Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.
About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.
Media Contact:
Arleen Goldenberg
Verge Scientific Communications
202.930.4762
More News
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC)...
read more
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more